Literature DB >> 18665077

Exon III splicing of fibroblast growth factor receptor 1 is modulated by growth factors and cyclin D1.

Guowei Chen1, Jian Wang, Zhanbing Liu, Marko Kornmann.   

Abstract

OBJECTIVES: Fibroblast growth factor receptor 1 (FGFR1) isoform IIIc enhances and FGFR1-IIIb inhibits pancreatic cancer cell growth. Nothing is presently known about the expression and regulation of human FGFR1-III isoforms. The aim of this study was to identify regulators modulating the specific expression of human FGFR1-IIIb and FGFR1-IIIc.
METHODS: Parental cells, cells overexpressing FGFR1-III isoforms, and cells harboring a tetracycline-inducible cyclin D1 antisense expression vector system were used as model systems.
RESULTS: FGFR1-IIIb and -IIIc were coexpressed in human pancreatic cancer cells, with FGFR1-IIIc being the predominant isoform. FGFR1-IIIb mRNA expression decreased at higher cell density, whereas FGFR1-IIIc expression remained constant. Insulinlike growth factor I and epidermal growth factor induced expression of FGFR1-IIIc without altering FGFR1-IIIb. In contrast, fibroblast growth factor (FGF)1, FGF2, and FGF5 induced FGFR1-IIIc and reduced the expression of FGFR1-IIIb. Overexpression of one isoform did not alter the expression of the corresponding FGFR1-III isoform. Inhibition of cyclin D1, known to be induced by insulinlike growth factor I, epidermal growth factor, and FGF2, resulted in an inhibition of FGFR1-IIIc expression, whereas FGFR1-IIIb expression was enhanced.
CONCLUSIONS: This study demonstrated for the first time that FGFR1-IIIb and FGFR1-IIIc are coexpressed and that the FGFR1-III isoformsare differentially regulated by growth factors and cyclin D1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18665077     DOI: 10.1097/MPA.0b013e31816618a4

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  5 in total

Review 1.  Molecular biology of pancreatic cancer.

Authors:  Cristóbal Belda-Iniesta; Immaculada Ibáñez de Cáceres; Jorge Barriuso; Javier de Castro Carpeño; Manuel González Barón; Jaime Feliú
Journal:  Clin Transl Oncol       Date:  2008-09       Impact factor: 3.405

2.  Complex alternative splicing of the smarca2 gene suggests the importance of smarca2-B variants.

Authors:  Min Yang; Yuan Sun; Ling Ma; Chenguang Wang; Jian-Min Wu; Anding Bi; D Joshua Liao
Journal:  J Cancer       Date:  2011-07-06       Impact factor: 4.207

Review 3.  Regulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in Cancer.

Authors:  Zahava Siegfried; Serena Bonomi; Claudia Ghigna; Rotem Karni
Journal:  Int J Cell Biol       Date:  2013-09-03

Review 4.  Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.

Authors:  Cherine Abou-Fayçal; Anne-Sophie Hatat; Sylvie Gazzeri; Beatrice Eymin
Journal:  Int J Mol Sci       Date:  2017-02-11       Impact factor: 5.923

5.  Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression.

Authors:  G Chen; X Tian; Z Liu; S Zhou; B Schmidt; D Henne-Bruns; M Bachem; M Kornmann
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.